Xiangmei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiangmei Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Bingyue Pan
College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China
1 shared publicationJiashuo Wu
College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China
1 shared publication- Junwei Han
College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China
1 shared publication - Xilong Zhao
College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China
1 shared publication - Yalan He
College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China
1 shared publication - Yongbao Zhang
College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China
1 shared publication
Latest Publications
- Open Access
- 10 June 2026
- Vol. 12 (24) , eaed6373
PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction
Immunotherapy has revolutionized cancer treatment, yet substantial inter-patient response heterogeneity limits therapeutic benefit to specific patient subsets. Here, we present PathTIGR, a pathway topology-informed graph representation learning framework that systematically integrates biological pathway network topology knowledge with genome variation information for immunotherapy response prediction. PathTIGR uses a three-component design: (i) pathway graph encoder with multihead attention embeding pathway topology knowledge and cancer genomic variants to pathway representation, (ii) transformer module capturing pathway regulatory dependencies, and (iii) multilayer perceptron synthesizing pathway-level representations to predict immunotherapy response. This architecture enables PathTIGR to capture complex molecular interactions underlying immunotherapy response. Comprehensive validation across multiple independent immunotherapy cohorts demonstrates that PathTIGR achieves superior predictive performance compared to established biomarkers and state-of-the-art deep learning approaches while maintaining biological interpretability through identification of key signatures underlying response heterogeneity. PathTIGR represents an interpretable graph-based learning framework that enhances immunotherapy response prediction and elucidates molecular determinants of therapeutic efficacy, thereby facilitating the advancement of precision cancer immunotherapy.
- 10 June 2026
- Vol. 12 (24) , eaed6373
Open AccessPathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction
Immunotherapy has revolutionized cancer treatment, yet substantial inter-patient response heterogeneity limits therapeutic benefit to specific patient subsets. Here, we present PathTIGR, a pathway topology-informed graph representation learning framework that systematically integrates biological pathway network topology knowledge with genome variation information for immunotherapy response prediction. PathTIGR uses a three-component design: (i) pathway graph encoder with multihead attention embeding pathway topology knowledge and cancer genomic variants to pathway representation, (ii) transformer module capturing pathway regulatory dependencies, and (iii) multilayer perceptron synthesizing pathway-level representations to predict immunotherapy response. This architecture enables PathTIGR to capture complex molecular interactions underlying immunotherapy response. Comprehensive validation across multiple independent immunotherapy cohorts demonstrates that PathTIGR achieves superior predictive performance compared to established biomarkers and state-of-the-art deep learning approaches while maintaining biological interpretability through identification of key signatures underlying response heterogeneity. PathTIGR represents an interpretable graph-based learning framework that enhances immunotherapy response prediction and elucidates molecular determinants of therapeutic efficacy, thereby facilitating the advancement of precision cancer immunotherapy.